Characteristics of the clinical populations in the GWAS
| . | Total transplants in the GWAS (N = 1589) . | aGVHD grade II-IV . | aGVHD grade III-IV . | ||
|---|---|---|---|---|---|
| Case (n = 622) . | Control (n = 967) . | Case (n = 229) . | Control (n = 1360) . | ||
| aGVHD grade, n (%) | |||||
| 0 | 536 (34) | — | 536 | — | 536 |
| I | 431 (27) | — | 431 | — | 431 |
| II | 393 (25) | 393 | — | — | 393 |
| III | 168 (11) | 168 | — | 168 | — |
| IV | 61 (3.8) | 61 | — | 61 | — |
| aGVHD organs,*n (%) | |||||
| Skin | — | 336 (54) | — | 41 (18) | — |
| Liver | — | 155 (25) | — | 96 (42) | — |
| Gut | — | 333 (53) | — | 152 (66) | — |
| Chronic GVHD,†n (%) | |||||
| No | 799 (57) | 239 (44) | 560 (64) | 75 (42) | 724 (59) |
| Limited | 212 (15) | 96 (17) | 116 (13) | 26 (15) | 186 (15) |
| Extended | 345 (24) | 176 (32) | 169 (19) | 57 (32) | 288 (23) |
| No data | 56 (4) | 32 (6) | 24 (3) | 19 (11) | 37 (3) |
| Median age, y (range) | 33 (0-70) | 34 (0-68) | 32 (0-70) | 34 (1-67) | 33 (0-70) |
| Sex of recipient-donor, n (%) | |||||
| Male-Male | 725 (46) | 280 (45) | 445 (46) | 103 (45) | 622 (46) |
| Male-Female | 267 (17) | 111 (18) | 156 (16) | 45 (20) | 222 (16) |
| Female-Male | 284 (18) | 109 (18) | 175 (18) | 44 (19) | 240 (18) |
| Female-Female | 313 (20) | 122 (20) | 191 (20) | 37 (16) | 276 (20) |
| GVHD prophylaxis, n (%) | |||||
| MTX + cyclosporine A | 945 (60) | 380 (61) | 565 (58) | 141 (62) | 804 (59) |
| MTX + tacrolimus | 644 (41) | 242 (39) | 402 (42) | 88 (38) | 556 (41) |
| ATG administration, n (%) | |||||
| Yes | 104 (6.5) | 19 (3.1) | 85 (8.8) | 9 (3.9) | 95 (7.0) |
| No | 1478 (93) | 600 (97) | 878 (91) | 220 (96) | 1258 (93) |
| Unknown | 7 (0.4) | 3 (0.5) | 4 (0.4) | 0 (0.0) | 7 (0.5) |
| No T-cell depletion, n (%) | 1589 (100) | 622 (100) | 967 (100) | 229 (100) | 1360 (100) |
| Preconditioning regimen, n (%) | |||||
| TBI regimen | 1214 (76) | 491 (79) | 723 (75) | 184 (80) | 1030 (76) |
| Non-TBI regimen | 372 (23) | 130 (21) | 242 (25) | 44 (19) | 328 (24) |
| Unknown | 3 (0.2) | 1 (0.2) | 2 (0.2) | 1 (0.4) | 2 (0.1) |
| Underlying disease, n (%) | |||||
| AML | 423 (27) | 151 (24) | 272 (28) | 56 (25) | 367 (27) |
| ALL | 379 (24) | 163 (26) | 216 (22) | 63 (28) | 316 (23) |
| CML | 243 (15) | 102 (16) | 141 (15) | 39 (17) | 204 (15) |
| MDS | 183 (12) | 72 (12) | 111 (12) | 26 (11) | 157 (12) |
| NHL | 169 (11) | 85 (14) | 84 (9) | 30 (13) | 139 (10) |
| Others | 192 (12) | 49 (8) | 143 (15) | 15 (7) | 177 (13) |
| HLA-DPB1 typing,‡n (%) | |||||
| Matched | 594 (37) | 176 (28) | 418 (43) | 65 (28) | 529 (39) |
| Mismatched | 995 (63) | 446 (72) | 549 (57) | 164 (72) | 831 (61) |
| . | Total transplants in the GWAS (N = 1589) . | aGVHD grade II-IV . | aGVHD grade III-IV . | ||
|---|---|---|---|---|---|
| Case (n = 622) . | Control (n = 967) . | Case (n = 229) . | Control (n = 1360) . | ||
| aGVHD grade, n (%) | |||||
| 0 | 536 (34) | — | 536 | — | 536 |
| I | 431 (27) | — | 431 | — | 431 |
| II | 393 (25) | 393 | — | — | 393 |
| III | 168 (11) | 168 | — | 168 | — |
| IV | 61 (3.8) | 61 | — | 61 | — |
| aGVHD organs,*n (%) | |||||
| Skin | — | 336 (54) | — | 41 (18) | — |
| Liver | — | 155 (25) | — | 96 (42) | — |
| Gut | — | 333 (53) | — | 152 (66) | — |
| Chronic GVHD,†n (%) | |||||
| No | 799 (57) | 239 (44) | 560 (64) | 75 (42) | 724 (59) |
| Limited | 212 (15) | 96 (17) | 116 (13) | 26 (15) | 186 (15) |
| Extended | 345 (24) | 176 (32) | 169 (19) | 57 (32) | 288 (23) |
| No data | 56 (4) | 32 (6) | 24 (3) | 19 (11) | 37 (3) |
| Median age, y (range) | 33 (0-70) | 34 (0-68) | 32 (0-70) | 34 (1-67) | 33 (0-70) |
| Sex of recipient-donor, n (%) | |||||
| Male-Male | 725 (46) | 280 (45) | 445 (46) | 103 (45) | 622 (46) |
| Male-Female | 267 (17) | 111 (18) | 156 (16) | 45 (20) | 222 (16) |
| Female-Male | 284 (18) | 109 (18) | 175 (18) | 44 (19) | 240 (18) |
| Female-Female | 313 (20) | 122 (20) | 191 (20) | 37 (16) | 276 (20) |
| GVHD prophylaxis, n (%) | |||||
| MTX + cyclosporine A | 945 (60) | 380 (61) | 565 (58) | 141 (62) | 804 (59) |
| MTX + tacrolimus | 644 (41) | 242 (39) | 402 (42) | 88 (38) | 556 (41) |
| ATG administration, n (%) | |||||
| Yes | 104 (6.5) | 19 (3.1) | 85 (8.8) | 9 (3.9) | 95 (7.0) |
| No | 1478 (93) | 600 (97) | 878 (91) | 220 (96) | 1258 (93) |
| Unknown | 7 (0.4) | 3 (0.5) | 4 (0.4) | 0 (0.0) | 7 (0.5) |
| No T-cell depletion, n (%) | 1589 (100) | 622 (100) | 967 (100) | 229 (100) | 1360 (100) |
| Preconditioning regimen, n (%) | |||||
| TBI regimen | 1214 (76) | 491 (79) | 723 (75) | 184 (80) | 1030 (76) |
| Non-TBI regimen | 372 (23) | 130 (21) | 242 (25) | 44 (19) | 328 (24) |
| Unknown | 3 (0.2) | 1 (0.2) | 2 (0.2) | 1 (0.4) | 2 (0.1) |
| Underlying disease, n (%) | |||||
| AML | 423 (27) | 151 (24) | 272 (28) | 56 (25) | 367 (27) |
| ALL | 379 (24) | 163 (26) | 216 (22) | 63 (28) | 316 (23) |
| CML | 243 (15) | 102 (16) | 141 (15) | 39 (17) | 204 (15) |
| MDS | 183 (12) | 72 (12) | 111 (12) | 26 (11) | 157 (12) |
| NHL | 169 (11) | 85 (14) | 84 (9) | 30 (13) | 139 (10) |
| Others | 192 (12) | 49 (8) | 143 (15) | 15 (7) | 177 (13) |
| HLA-DPB1 typing,‡n (%) | |||||
| Matched | 594 (37) | 176 (28) | 418 (43) | 65 (28) | 529 (39) |
| Mismatched | 995 (63) | 446 (72) | 549 (57) | 164 (72) | 831 (61) |
—, Not applicable; ALL, acute lymphocytic leukemia; AML, acute myelocytic leukemia; ATG, anti-thymocyte globulin; CML, chronic myelocytic leukemia; MDS, myelodysplastic syndrome; MTX, methotrexate; NHL, non-Hodgkin lymphoma; TBI, total body irradiation.
Only relevant stages for GVHD grade II-IV or II-IV are shown: skin stage ≥3, liver stage ≥1, gut stage ≥1 for GVHD grade II-IV; skin stage 4, liver stage ≥2, gut stage ≥2 for GVHD grade III–IV.
Excluding deaths before day 100 (177 excluded).
Allele mismatch is defined in GVH direction.